Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Related articles:
Related suggestion:
People enjoy outdoor activities as spring flowers bloom across ChinaAho, Martinook cap Hurricanes' late rally to beat the Islanders for a 2China, U.S. make preparations to send a pair of giant pandas to San Francisco Zoo in 2025Fish farm develops into tourist hotspot in exploration of modern aquacultureEcuador violence: Ecuadorians approve referendum measures to toughen fight against gangsBo Bichette has 3Matthews scores as Maple Leafs beat Bruins 3US House Judiciary Committee chair seeks details from ATF on airport director shootingUK home secretary to visit Italy to discuss stopping migrants arriving on boatsCruz breaks slump with 3 hits, Jones cruises as Pirates beat Brewers 4
1.9924s , 5764.453125 kb
Copyright © 2024 Powered by Medicare can pay for obesity drugs like Wegovy in certain heart patients ,International Investigation news portal